The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ERIC 2022 | Common genetic tests in CLL & when these tests should be performed
Richard Rosenquist, MD, PhD, Karolinska Institute, Stockholm, Sweden, discusses how molecular analysis is now used more frequently for patients with chronic lymphocytic leukemia (CLL) and describes the three most common tests performed – FISH analysis, TP53 sequencing and IGHV gene mutation status. Dr Rosenquist also details how TP53 mutations can emerge abruptly, explaining that these types of molecular tests should be done before treatment initiation and at relapse. This interview took place at the 2022 European Research Initiative on CLL (ERIC) Meeting.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
